Evidence mapPaperPMID 40458176Full record

SynthesisFrontiers in endocrinology2025

Thyroid disorders and COVID-19: a comprehensive review of literature.

Narges Anbardar, Shanai Lashayla Dixon, Samhitha Munugoti, Maneesh Gaddam, Kebria Kashfi, Lillian Kasulis, Andrew L Messersmith, Kamyar Asadipooya

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Narges AnbardarDepartment of Clinical Medicine, St Matthew's University School of Medicine, Grand Cayman, FL, United States.
Shanai Lashayla DixonDepartment of Clinical Medicine, St Matthew's University School of Medicine, Grand Cayman, FL, United States.
Samhitha MunugotiDivision of Endocrinology, Diabetes, and Metabolism, University of Kentucky, Lexington, KY, United States.
Maneesh GaddamPulmonary, Critical Care and Sleep Medicine, Appalachian Regional Healthcare, Hazard, KY, United States.
Kebria KashfiDepartment of Clinical Medicine, American University of Antigua College of Medicine, Coolidge, AG, United States.
Lillian KasulisDepartment of Clinical Medicine, American University of Antigua College of Medicine, Coolidge, AG, United States.
Andrew L MessersmithDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Barnstable Brown Diabetes and Obesity Center, University of Kentucky, Lexington, KY, United States.
Kamyar AsadipooyaDepartment of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Barnstable Brown Diabetes and Obesity Center, University of Kentucky, Lexington, KY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The literature is rapidly evolving with regards to the endocrine consequences of coronavirus disease 2019 (COVID-19), including diabetes, thyroid dysfunction, adrenal and pituitary disorders. There is evidence suggesting that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can lead to thyroid dysfunction and long-term sequelae. We aimed to review the current evidence and propose a preventive approach based on the published data since the beginning of the COVID-19 pandemic. Methods: A comprehensive review of literature was conducted using electronic databases PubMed and Google Scholar. Two authors independently used the keywords "Thyroid, Hypothyroidism, Hyperthyroidism, Graves, Thyroid Eye Disease, or Thyroiditis" and "Coronavirus, SARS-CoV-2 or COVID-19" to search these databases. We screened titles and abstracts for initial selection and then reviewed the full text of relevant studies to report the outcomes of published data. Results: We selected 28 manuscripts. SARS-CoV-2 infection appears similar to other viruses. It affects thyroid function resulting in non-thyroidal illness syndrome, which usually resolves spontaneously. COVID-19 also causes subacute thyroiditis. It may also trigger autoimmunity against the thyroid that leads to autoimmune thyroiditis. Autoimmune thyroiditis or subacute thyroiditis may progress to clinical or subclinical hypothyroidism and clinical or subclinical hyperthyroidism. Patients with pre-existing thyroid dysfunction probably have similar risks of SARS-CoV-2 related adverse outcomes. Conclusions: Evaluation of thyroid function is important in COVID-19 patients. Improving the efficacy of treatment against acute SARS-CoV-2 infection can reduce the risks of short-term and long-term complications. Systematic Review Registration: https://www.crd.york.ac.uk/prospero, identifier CRD42023447994.

Indexed as

COVID-19Thyroid DiseasesHumansSARS-CoV-2ACE2hyperthyroidismhypothyroidismSARS-CoV-2thyroiditis

Identifiers

PMID40458176
PMCPMC12127173

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.